sinc
septemb
laboratoryconfirm
case
human
infect
middl
east
respiratori
syndrom
coronaviru
merscov
offici
report
world
health
organ
juli
includ
least
relat
death
fatal
rate
http
symptom
caus
merscov
infect
includ
fever
cough
short
similar
caus
sever
acut
respiratori
syndrom
coronaviru
srascov
fatal
rate
epidem
contrast
sarscov
highli
merscov
remain
rather
limit
transmiss
nevertheless
accumul
evid
show
persontoperson
transmiss
viru
among
close
may
june
outbreak
merscov
infect
consider
number
case
republ
juli
mer
case
includ
one
secondari
infect
case
travel
guangdong
provinc
china
confirm
death
caus
http
wwwwprowhointoutbreaksemergencieswprocoronavirusen
addit
also
case
confirm
thailand
philippin
saudi
arabia
unit
arab
period
http
rais
longterm
concern
merscov
could
becom
pandem
futur
therefor
urgent
need
develop
effect
measur
counter
threat
global
public
health
howev
neither
vaccin
antivir
therapeut
avail
prevent
treat
mer
thu
far
monoclon
antibodi
mab
potent
neutral
activ
promis
candid
prophylact
therapeut
intervent
viru
infect
coronavirus
viral
compon
frequent
target
antibodi
surfaceloc
envelop
spike
glycoprotein
normal
cleav
subunit
mediat
receptor
recognit
membran
fusion
accordingli
merscov
enter
target
cell
initi
interact
subunit
cellular
receptor
human
also
known
dipeptidyl
peptidas
subsequ
fusion
viral
envelop
host
cell
lipid
bilay
mediat
other
previous
dissect
entri
process
merscov
present
structur
receptorbind
domain
rbd
complex
atom
structur
fusion
structur
studi
clearli
show
rbd
merscov
mersrbd
compos
core
subdomain
extern
subdomain
directli
interact
receptor
via
extern
thu
disrupt
interact
mersrbd
mab
could
use
therapi
merscov
infect
inde
sever
vaccin
studi
experiment
anim
demonstr
polyclon
antibodi
induc
mersrbd
strongli
inhibit
addit
two
group
recent
report
isol
human
mab
potent
neutral
activ
bcell
repertoir
healthi
one
group
util
velocimmun
technolog
velocigen
technolog
rapidli
develop
fulli
human
neutral
mab
mab
target
rbd
region
merscov
neutral
result
indic
mersrbd
behav
welldefin
protein
entiti
could
use
use
immunogen
neutral
mab
product
howev
efficaci
antibodi
merscov
vivo
mechan
neutral
remain
unclear
studi
report
gener
two
mousederiv
neutral
mab
merscov
mice
immun
mersrbd
character
mab
use
panel
biochem
biophys
cell
biolog
method
show
two
mab
probabl
recogn
proxim
overlap
epitop
neutral
viru
interf
protein
bind
subsequ
solv
structur
bound
mersrbd
neutral
determin
structur
delin
atom
level
furthermor
also
human
base
solv
structur
demonstr
result
human
antibodi
exhibit
similar
neutral
activ
biochem
charact
parent
mous
antibodi
final
human
mab
test
vivo
shown
significantli
reduc
viru
titer
merscovinfect
mice
gener
mab
capabl
neutral
merscov
mice
immun
recombin
mersrbd
protein
prepar
insect
cell
subsequ
stabl
hybridoma
cell
line
gener
screen
posit
clone
initi
elisa
panel
clone
reactiv
mersrbd
therefor
test
capac
interfer
interact
fluorescenceactiv
cell
sort
fac
competit
bind
assay
solubl
mersrbd
fcfusion
protein
incub
cell
without
gener
mab
two
clone
design
respect
shown
potent
inhibit
bind
mersrbd
figur
contrast
mab
eg
appreci
interfer
interact
figur
therefor
select
irrelev
antibodi
mous
mab
direct
ebvvca
neg
control
throughout
vitro
studi
merscov
infect
cell
initi
interact
mersrbd
result
competit
bind
assay
strongli
suggest
may
possess
neutral
activ
test
hypothesi
first
analyz
bind
kinet
two
mab
mersrbd
surfac
plasmon
reson
spr
bind
avid
calcul
dissoci
constant
kd
nm
nm
respect
figur
valu
demonstr
modestli
subdu
affin
comparison
mersrbd
determin
nm
previou
select
mab
test
potenti
inhibit
merscov
entri
suscept
cell
either
pseudotyp
infecti
virus
expect
neither
abl
neutral
merscov
infect
howev
exhibit
potent
neutral
activ
viru
infect
figur
neutral
dose
determin
nm
pseudoviru
nm
live
viru
respect
valu
nm
nm
demonstr
slightli
better
neutral
potenc
analyz
bind
mersrbd
use
octet
antihi
biosensor
captur
mersrbd
first
satur
one
antibodi
load
anoth
antibodi
evalu
bind
data
clearli
show
compet
bind
mersrbd
figur
indic
proxim
overlap
epitop
probabl
recogn
two
mab
collect
result
suggest
inhibit
merscov
entri
host
cell
block
viru
bind
cellular
receptor
differenti
effici
neutral
like
result
differ
bind
affin
andor
epitop
recogn
antibodi
isotyp
belong
subtyp
sequenc
indic
germlin
gene
segment
gener
two
mab
differ
variabl
v
gene
segment
tabl
v
region
heavi
chain
exhibit
ident
amino
acid
sequenc
wherea
v
region
light
chain
higher
ident
expect
two
mab
distinct
complementar
determin
region
cdr
varianc
observ
differ
sequenc
length
heavi
chain
tabl
data
demonstr
uniqu
also
suggest
two
mab
target
differ
epitop
mersrbd
next
use
xray
crystallographi
explor
neutral
mechan
antibodi
better
defin
epitop
recogn
fabmersrbd
complex
individu
prepar
subject
extens
crystal
screen
howev
unabl
crystal
complex
crystal
bound
mersrbd
obtain
structur
complex
solv
resolut
tabl
final
model
rwork
rfree
contain
two
complex
per
crystallograph
asymmetr
unit
one
complex
show
much
clearer
electron
densiti
util
subsequ
structur
analys
overal
paratop
involv
six
cdr
interact
extens
mainli
extern
subdomain
mersrbd
heavi
chain
light
chain
contribut
almost
equal
epitop
recognit
togeth
buri
surfac
area
viral
ligand
reciproc
major
element
mersrbd
recogn
includ
helix
strand
connect
interloop
loop
clip
antibodi
tipcentr
vdomain
bind
mode
orient
away
extern
sheetfac
accord
previou
respons
direct
interact
figur
superimposit
structur
previous
report
structur
complex
pdb
code
reveal
bound
converg
almost
perpendicularli
recogn
larg
differ
surfac
patch
viral
ligand
figur
close
proxim
led
strong
steric
clash
least
two
region
one
relat
loop
heavi
chain
collid
carbohydr
moieti
receptor
lie
de
loop
heavi
chain
vdomain
bump
loop
preced
extend
propel
blade
iv
figur
also
compar
footprint
mersrbd
character
interfac
residu
locat
within
distanc
bound
antibodi
receptor
though
amino
acid
recogn
distinct
interact
five
residu
includ
overlap
two
footprint
figur
henc
could
interfer
interact
present
strong
steric
hindranc
compet
residu
therebi
neutral
viru
infect
figur
amino
acid
interact
bind
interfac
mersrbd
character
individu
six
cdr
heavi
chain
contribut
epitop
bind
stack
residu
amino
acid
mersrbd
figur
nevertheless
interact
site
rather
limit
moder
number
van
der
waal
vdw
contact
tabl
contrast
heavi
chain
engag
viral
ligand
much
broader
manner
provid
multipl
tabl
vdw
sever
figur
hbond
interact
former
includ
residu
contact
mainli
mersrbd
figur
latter
involv
antibodi
interact
ligand
residu
figur
light
chain
import
epitop
recognit
contrast
heavi
chain
reli
mostli
ligand
engag
total
vdw
contact
tabl
individu
contribut
respect
involv
antibodi
viral
ligand
figur
howev
provid
vdw
interact
tabl
stack
residu
mersrbd
amino
acid
figur
addit
observ
strengthen
bind
extra
hbond
figur
reciproc
aforement
bind
detail
demonstr
mersrbd
residu
form
conform
epitop
recogn
tabl
potent
neutral
activ
indic
potenti
clinic
applic
prevent
treat
mer
passiv
immunotherapeut
agent
therefor
sought
human
antibodi
time
maintain
capac
bind
mersrbd
detail
inform
bind
hand
tailor
human
strategi
antibodi
two
aspect
first
find
human
antibodi
highest
sequenc
ident
second
preserv
interfac
residu
use
blast
antiplasmodium
falciparum
merozoit
surfac
protein
genbank
access
number
exhibit
sequenc
ident
heavi
chain
variabl
domain
antibodi
select
templat
human
subsequ
human
sequenc
therebi
compris
scaffold
residu
amino
acid
cdr
maintain
bind
potenc
mersrbd
interfac
residu
flank
light
chain
includ
also
swap
human
antibodi
addit
residu
eg
light
chain
locat
middl
cdr
loop
therefor
play
role
maintain
proper
fold
ligand
recognit
also
preserv
wherea
heavi
chain
resid
end
f
strand
therebi
unlik
affect
conform
adjac
loop
replac
equival
human
residu
figur
human
prepar
fulllength
antibodi
protein
cell
purifi
homogen
first
character
interact
mersrbd
spr
bind
kinet
reveal
kd
nm
figur
compar
interact
figur
consist
could
potent
block
mersrbd
bind
express
surfac
cell
flow
cytometr
assay
figur
neutral
activ
merscov
infect
investig
calcul
determin
nm
pseudoviru
nm
live
viru
respect
figur
valu
similar
observ
figur
therefor
human
antibodi
exhibit
almost
ident
efficaci
parent
mous
antibodi
neutral
viru
infect
vitro
final
human
mab
test
vivo
protect
efficaci
use
previous
describ
mous
singl
dose
antibodi
intraven
administ
mice
one
day
merscov
challeng
viral
titer
lung
monitor
day
post
infect
dpi
phosphat
buffer
salin
pb
irrelev
antibodi
use
chimer
antibodi
target
ebola
viru
gp
isoantibodi
control
group
viral
load
plateau
pfug
tissu
dpi
decreas
tissu
dpi
decreas
pfug
tissu
dpi
figur
protect
test
pre
postinfect
treatment
mice
significantli
abat
viru
titer
lung
case
viral
load
decreas
order
magnitud
pfug
tissu
dpi
lower
limit
detect
pfug
tissu
dpi
figur
result
demonstr
vivo
efficaci
indic
potenti
applic
human
merscov
prophylax
also
therapeut
treatment
emerg
merscov
infect
pose
seriou
global
threat
public
health
effect
measur
counteract
viru
infect
therefor
need
studi
rhesu
macaqu
shown
combin
ribavirin
interferon
effect
primari
treatment
prophylaxi
nevertheless
combin
strategi
test
patient
investig
larg
random
clinic
neither
effect
drug
vaccin
treat
prevent
merscov
infect
neutral
antibodi
shown
variou
viru
infect
cancer
remark
capac
clinic
applic
especi
recent
work
ebola
diseas
treatment
mab
could
repres
import
strateg
reserv
prepar
potenti
pandem
studi
isol
character
two
mous
neutral
mab
exhibit
one
two
digit
nanomolar
merscov
infect
assess
use
pseudotyp
infecti
virus
mab
demonstr
competit
inhibit
bind
mersrbd
therebi
disrupt
virusreceptor
interact
dissect
epitoperecognit
basi
determin
structur
antibodi
bound
mersrbd
human
antibodi
preserv
interfac
residu
furthermor
protect
efficaci
human
mab
valid
vivo
result
herebi
contribut
global
effort
control
merscov
infect
transmiss
provid
one
wellcharacter
neutral
mab
via
xray
crystallographi
abl
map
exact
epitop
recogn
viral
ligand
conform
epitop
compos
mersrbd
residu
figur
tabl
interest
region
larg
differ
receptorbind
interfac
engag
figur
though
sever
interfac
residu
inde
share
antibodi
receptor
competit
inhibit
receptor
bind
therefor
larg
attribut
steric
hindranc
creat
upon
antibodi
engag
especi
antibodi
heavi
chain
carbohydr
receptor
mechan
seem
separ
antibodi
isol
tang
et
nonimmun
human
abphag
librari
major
epitop
region
human
mab
eg
ab
map
receptorbind
motif
directli
interfac
mutat
posit
identifi
escap
mutant
could
complet
abrog
neutral
activ
mab
howev
engag
contact
neglig
vdw
interact
vdw
contact
respect
tabl
therefor
unlik
substitut
residu
would
also
compromis
activ
furthermor
though
multipl
rbd
mutat
identifi
natur
variant
human
merscov
none
involv
epitop
recip
given
advantag
use
cocktail
neutral
mab
target
noncrossresist
epitop
thu
decreas
possibl
viral
escap
human
antibodi
would
use
addit
formul
antimerscov
antibodi
mab
exhibit
slightli
better
neutral
activ
littl
higher
bind
affin
mersrbd
despit
great
effort
unabl
crystal
mersrbd
nevertheless
show
compet
bind
site
viral
ligand
demonstr
proxim
overlap
epitop
probabl
share
two
mab
group
togeth
combin
potenti
applic
combin
immunotherapi
discuss
human
antibodi
human
epitop
character
carri
futur
studi
human
instruct
structur
antibodi
bound
mersrbd
switch
sequenc
homolog
human
antibodi
sequenc
preserv
interfac
residu
manag
human
antibodi
maxim
simultan
maintain
bind
capac
viral
ligand
noteworthi
bind
unlik
major
structur
defin
antibodyantigen
reli
loop
region
vdw
contact
contact
contact
region
loop
defin
threeresidu
motif
compos
base
imgt
data
account
approxim
half
vdw
contact
contribut
four
amino
acid
flank
includ
provid
half
vdw
interact
therefor
retain
human
antibodi
accordingli
neutral
test
inde
show
human
exhibit
similar
inhibitori
activ
merscov
infect
parent
mous
antibodi
vitro
also
abat
viru
titer
effici
vivo
highlight
advantag
structurebas
human
strategi
despit
recent
success
identifi
mab
target
sever
differ
virus
human
antibodi
convent
method
initi
isol
neutral
mab
immun
anim
eg
mice
subsequ
human
mab
therapeut
applic
remain
domin
strategi
mab
discoveri
work
present
exampl
bridg
identif
human
step
via
crystallographi
mab
target
merscov
similar
strategi
might
appli
virus
merscov
rbd
prepar
bactobac
baculoviru
express
system
previous
briefli
code
sequenc
merscov
rbd
genbank
access
number
spike
residu
ligat
vector
signal
peptid
protein
secret
hexahi
tag
facilit
purif
process
protein
purifi
sequenti
appli
histrap
hp
column
ge
healthcar
superdex
column
ge
healthcar
merscov
rbdfc
residu
protein
also
prepar
briefli
code
sequenc
fuse
fragment
code
fc
domain
mous
clone
pcagg
express
vector
plasmid
transfect
cell
use
lipofectamin
invitrogen
cell
cultur
collect
h
transfect
use
stain
directli
mice
immun
purifi
merscov
rbd
protein
splenocyt
hyper
immun
mice
fuse
myeloma
cell
posit
clone
select
elisa
use
merscov
rbd
larg
amount
mab
purifi
hitrap
protein
g
hp
ge
healthcar
bind
buffer
mm
sodium
phosphat
ph
elut
buffer
glycin
acidhcl
ph
purifi
mab
digest
mous
fab
f
prepar
kit
thermo
scientif
accord
manufactur
instruct
fragment
fab
purifi
hitrap
protein
ff
ge
healthcar
exchang
buffer
mm
tri
ph
mm
nacl
merscov
rbd
fab
fragment
mix
molar
ration
mixtur
incub
ice
min
purifi
gel
filtrat
mgml
pool
protein
use
crystal
initi
screen
trial
perform
vapourdiffus
sittingdrop
method
normal
protein
reservoir
solut
mix
seal
equilibr
reservoir
solut
diffract
crystal
obtain
condit
consist
sodium
thiocyan
wv
peg
collect
diffract
data
crystal
flashcool
liquid
nitrogen
incub
reservoir
solut
contain
vv
glycerol
data
set
collect
high
energi
acceler
research
organ
kek
wavelength
data
process
initi
phase
determin
molecular
replac
phaser
suit
subsequ
model
build
refin
perform
use
coot
phenix
refin
result
respect
structur
figur
gener
use
pymol
http
wwwpymolorg
fv
region
human
accord
crystal
structur
mersrbd
bound
fab
brief
mersrbdinteract
residu
sustain
nonrel
amino
acid
replac
counterpart
local
homolog
human
antibodi
sequenc
genbank
access
number
human
fv
gene
synthes
genewiz
compani
optim
express
mammalian
cell
constant
region
light
chain
heavi
chain
replac
human
antiinfluenza
mab
genbank
access
number
human
immunoglobulin
heavi
chain
genbank
access
number
respect
complet
light
chain
heavi
chain
individu
obtain
overlap
pcr
clone
pcagg
express
vector
light
chain
fuse
hexahi
tag
cterminu
plasmid
contain
human
light
chain
heavi
chain
cotransfect
cell
medium
chang
without
serum
h
transfect
medium
collect
h
later
pass
hitrap
protein
g
hp
purifi
human
antibodi
purifi
chang
pb
solut
storag
obtain
cell
surfaceexpress
fuse
egfp
protein
fulllength
code
sequenc
genbank
access
number
clone
vector
genbank
access
number
ligat
vector
plasmid
transfect
separ
cell
cell
collect
h
transfect
resuspend
pb
cell
ml
stain
experi
perform
room
temperatur
antibodi
neg
control
incub
merscov
rbdfc
min
mixtur
use
stain
cell
express
respect
min
cell
wash
time
use
pb
incub
tritclabel
antimous
secondari
igg
antibodi
zsgbbio
anoth
min
wash
cell
analyz
flow
cytometri
bd
fac
aria
iii
machin
spr
analysi
perform
room
temperatur
use
biacor
machin
chip
ge
healthcar
analys
hbsep
buffer
consist
mm
hepe
ph
mm
nacl
vv
tween
use
protein
exchang
buffer
advanc
via
gel
filtrat
blank
channel
chip
use
neg
control
antibodi
immobil
chip
respons
unit
merscov
rbd
gradient
concentr
nm
nm
flow
chip
surfac
cycl
sensor
surfac
regener
mm
bind
kinet
analyz
softwar
bia
evalu
version
use
langmuir
bind
model
merscov
rbd
immobil
antihi
biosensor
associ
fab
fab
measur
octet
fortebio
inc
expos
sensor
nm
fab
kinet
buffer
degre
addit
bind
assess
expos
sensor
second
fab
nm
kinet
buffer
presenc
first
fab
nm
mer
pseudoviru
prepar
titrat
determin
perform
briefli
plasmid
pcaggsmerss
cotransfect
cell
cultur
mm
dish
h
supernat
contain
pseudoviru
harvest
centrifug
filter
steril
membran
singl
use
aliquot
ml
store
tissu
cultur
infecti
dose
determin
infect
neutral
assay
pseudoviru
incub
serial
dilut
antibodi
ngml
ngml
min
mixtur
use
infect
cell
seed
plate
repeat
h
incub
medium
replac
dmem
contain
fetal
bovin
serum
fb
sampl
incub
addit
h
luciferas
activ
measur
use
glomax
micropl
luminomet
promega
neutral
dose
calcul
use
prism
infecti
merscov
neutral
assay
perform
previous
describ
use
clinic
isol
merscov
strain
kindli
provid
r
fouchier
zaki
briefli
vero
cell
seed
per
well
cultur
plate
h
use
serial
dilut
ml
mab
unrel
mab
mab
ebvvca
includ
neg
control
prepar
tissu
cultur
plate
mem
medium
supplement
fc
equal
volum
merscov
work
stock
contain
ad
antibodyviru
mixtur
incub
h
antibodyviru
mixtur
ad
microtit
plate
contain
equal
volum
confluent
vero
cell
duplic
incub
incub
day
cell
infect
merscov
without
viru
appli
posit
uninfect
control
respect
cytopath
effect
cpe
well
observ
daili
record
day
infect
viru
backtitr
perform
assess
correct
viru
titer
use
experi
neutral
titer
mab
determin
highest
dilut
serum
complet
suppress
cpe
well
experi
perform
four
time
follow
standard
oper
procedur
approv
biosafeti
facil
previous
specif
pathogenfre
week
balbc
mice
purchas
nation
cancer
institut
mice
maintain
anim
care
facil
univers
iowa
protocol
approv
univers
iowa
institut
anim
care
use
committe
recombin
adenovir
vector
express
prepar
previous
african
green
monkey
kidneyderiv
cell
atcc
grown
dulbecco
modifi
eagl
medium
dmem
gibco
grand
island
ny
supplement
fb
merscov
strain
passag
cell
titter
cell
line
plaqu
assay
mice
lightli
anesthet
isofluran
transduc
intranas
pfu
dmem
antibodi
prophylax
day
post
transduct
mice
treat
antibodi
pb
mg
per
kilogram
bodi
weight
intraven
next
day
mice
infect
intranas
merscov
pfu
total
volum
dmem
antibodi
treatment
mice
inject
intraven
individu
antibodi
one
day
infect
mice
monitor
daili
morbid
mortal
lung
tissu
mice
collect
dpi
viru
titer
test
work
merscov
conduct
univers
iowa
biosafeti
level
laboratori
obtain
viru
load
lung
remov
pb
homogen
use
manual
homogen
viru
titter
cell
cell
fix
formaldehyd
stain
crystal
violet
dpi
merscov
titer
express
pfug
tissu
student
ttest
use
analyz
differ
mean
valu
among
differ
group
result
express
mean
sd
p
valu
consid
statist
signific
crystal
structur
complex
mersrbd
deposit
pdb
access
code
